Griffin reiterates Hana Biosciences at buy

Griffin Securities Inc. analyst Chrystyna Bedrij reiterated research coverage on Hana Biosciences Inc. with a buy rating, raising the 12-month price target range to $18 to $21. Shares of the South San Francisco biopharmaceutical company were up 16 cents, or 1.58%, at $10.30 on volume of 171,800 shares versus the three-month running average of 163,948 shares. (Amex: HBX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.